Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual ...

SMT appoints Bhargav Kotadia as CEO and Jose Calle Gordo as Chairman, driving growth and innovation in cardiovascular devices ...

The peripheral vascular stent market is projected to grow from USD 4,267.70 million in 2024 to USD 8,878.00 million by 2034, at a CAGR of 7.60%. Rising cases of peripheral artery disease (PAD) are ...

利用DPPA通过Mitsunobu反应取代羟基合成叠氮化物的文章（点击：），但 Mitsunobu反应会生成大量的副产物，不易纯化。下面介绍一种可以得到相同产物的方法，利用DPPA和DBU，可以取代羟基得到构型翻转的叠氮化物，此反应生成副产物 ...

To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

FAME 3 shows women fare similarly with PCI or CABG, while men benefit more from CABG for three-vessel disease.

Cardiac stent maker Sahajanand Medical Technologies Ltd, which is backed by private equity firms Morgan Stanley PE Asia ...

For heart attack patients who had undergone drug-eluting stenting, de-escalating dual antiplatelet therapy to ticagrelor (Brilinta) monotherapy cut bleeding risks in a meta-analysis of three ...